Biosergen (8N10) Stock Overview

A biotech company, develops antifungal drugs. More details

8N10 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (€259K)

Makes less than USD$1m in revenue (SEK0)

Highly volatile share price over the past 3 months compared to the German market

8N10 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,039 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

439,039 investors already sharing narratives

View all narratives

Biosergen AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biosergen
Historical stock prices
Current Share Price	SEK 0.10
52 Week High	SEK 4.58
52 Week Low	SEK 0.076
Beta	-0.079
1 Month Change	-75.93%
3 Month Change	-84.39%
1 Year Change	-97.25%
3 Year Change	-98.51%
5 Year Change	-99.90%
Change since IPO	-99.85%

Recent updates

Shareholder Returns

	8N10	DE Biotechs	DE Market
7D	-10.4%	-0.8%	-1.8%
1Y	-97.2%	-4.9%	4.2%

Return vs Industry: 8N10 underperformed the German Biotechs industry which returned -8.6% over the past year.

Return vs Market: 8N10 underperformed the German Market which returned 3.6% over the past year.

Price Volatility

Is 8N10's price volatile compared to industry and market?
8N10 volatility
8N10 Average Weekly Movement	22.2%
Biotechs Industry Average Movement	5.5%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.6%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 8N10's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8N10's weekly volatility has increased from 16% to 22% over the past year.

About the Company

Founded	Employees	CEO	Website
2004	1	Tine Olesen	www.biosergen.net

Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Biosergen AB (publ) Fundamentals Summary

How do Biosergen's earnings and revenue compare to its market cap?
8N10 fundamental statistics
Market cap	€258.74k
Earnings (TTM)	-€2.87m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is 8N10 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8N10 income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 32.32m
Earnings	-SEK 32.32m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-13.76
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 8N10 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/11 05:51
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biosergen AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Herman Kuntscher	Carlsquare AB

Biosergen (8N10) Stock Overview

Risk Analysis

Join community and earn perks

Biosergen AB (publ) Competitors

bioXXmed

Respiratorius

Biomark Diagnostics

Genetic Analysis

Price History & Performance

Recent News & Updates

New major risk - Financial position

New minor risk - Share price stability

Less than half of directors are independent

Biosergen AB (Publ) Appoints Mattias Klintemar as Chairman of the Board

Flerie AB (publ) (OM:FLERIE) agreed to acquire Biosergen AB (publ) (OM:BIOSGN) from Östersjöstiftelsen, Ribbskottet AB and others for SEK 1.5 million.

Biosergen AB (publ), Annual General Meeting, Jun 30, 2026

Recent updates

New major risk - Financial position

New minor risk - Share price stability

Less than half of directors are independent

Biosergen AB (Publ) Appoints Mattias Klintemar as Chairman of the Board

Flerie AB (publ) (OM:FLERIE) agreed to acquire Biosergen AB (publ) (OM:BIOSGN) from Östersjöstiftelsen, Ribbskottet AB and others for SEK 1.5 million.

Biosergen AB (publ), Annual General Meeting, Jun 30, 2026

Biosergen AB (publ) to Report Q1, 2026 Results on May 06, 2026

Biosergen AB (publ), Annual General Meeting, May 19, 2026

Biosergen AB Announces Chief Financial Officer Changes

Biosergen AB (Publ) Elects Marco Taglietti as Member of the Board of Directors and Establishes Nomination Committee

Biosergen AB to Report Q3, 2025 Results on Nov 19, 2025

Biosergen AB, Annual General Meeting, Jun 11, 2025

Biosergen AB Announces Completion of Treatment for the Second Cohort of Biosergen Clinical Trial for Its Antifungal Drug Candidate, BSG005

Biosergen AB Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial

Biosergen AB Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections

Biosergen to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial

Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections

Biosergen AB Completes Enrollment of First Cohort in Biosergen Proof-Of-Concept Trial

Biosergen Completes Treatment of the First Patient with BSG005

Biosergen on Dosing the First Patient with Life-Threatening Fungal Disease

Biosergen AB Announces First Patient in Biosergen Clinical Trial Treating with Biosergen for Life Threatening Fungal Infection

Biosergen AB Approves Board Changes

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

New major risk - Shareholder dilution

Biosergen AB to Report Q3, 2024 Results on Nov 29, 2024

Biosergen AB Receives Regulatory Approval to Test Lead Candidate Bsg005 in Patients with Invasive Fungal Infection

Biosergen AB Announces CEO Changes

Biosergen AB Announces Transition of Peder M. Andersen into A Chief Medical Officer Role

Biosergen AB, Annual General Meeting, May 31, 2024

High number of new and inexperienced directors

Biosergen AB Announces Lena Degling Wikingsson and Hanne Mette Dyrlie Kristensen Declines Re-Election as Board Members

High number of new and inexperienced directors

Biosergen Completes the First Multiple Ascending Dose Cohort of BSG005 Phase I Trial

Biosergen AB Announcest First Volunteer Has Been Dosed in the Mad Part of the Phase I Trial of BSG005

High number of new and inexperienced directors

High number of new and inexperienced directors

Biosergen AB Moves into Multiple Ascending Dose Part of Its Phase I Study After 4 Cohorts Tested in the SAD Part of Study

Biosergen Completes the Third Cohort of BSG005 Phase I Trial

Biosergen AB Successfully Completes Second Cohort of Bsg005 Phase I Trial

Biosergen Successfully Completes First Cohort of Bsg005 Phase I Trial

Biosergen Prepares Phase 2 Study in Mucormycosis Infected Patients

Biosergen AB Announces the First Subjects Dosed Successfully with No Adverse Events in the Phase I Trial of Bsg005

Biosergen AB Announces the First Volunteer Has Been Dosed with the Proprietary Antifungal Drug Candidate BSG005

Biosergen’s Application to Start Human Clinical Trials with BSG005

Shareholder Returns

Price Volatility

About the Company

Biosergen AB (publ) Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources